Verastem Oncology Data Suggests Broader Efficacy for…

Event summary

Verastem Oncology presented new molecular profiling and external control arm analyses for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC) at IGCS 2026.
In KRAS wild-type LGSOC patients, the combination achieved a 18% ORR and 13-month mPFS in triple wild-type (KRAS/NRAS/BRAF) tumors, and a 22% ORR in NRAS/BRAF-mutated tumors.
External control arm analysis showed weighted ORR of 38.7% and mPFS of 22.1 months in KRAS-mutated LGSOC vs. 0% ORR and 6.5 months mPFS with conventional care.
Japanese patient data (RAMP 201J) showed 44% ORR and 94% disease control rate across all patients, with 71% ORR in KRAS-mutated tumors.

The big picture

Verastem Oncology's data suggests its avutometinib-defactinib combination could offer meaningful benefits for a broader population of LGSOC patients, including those with KRAS wild-type tumors. This positions the therapy as a potential alternative to conventional care, which has historically shown limited efficacy in these subgroups. The findings come as the company seeks to expand the approved use of its therapy beyond KRAS-mutated LGSOC, a move that could significantly increase its addressable market.

What we're watching

Regulatory Pathway: Whether the expanded efficacy data will support broader FDA approval beyond KRAS-mutated LGSOC.
Market Differentiation: How Verastem positions the combination therapy against existing treatments for LGSOC.
Clinical Validation: The pace at which confirmatory Phase 3 trial (RAMP 301) results will be available to solidify the treatment's clinical benefit.